Position in NTLA
as of Mar 31, 2026
· filed Apr 21, 2026
Position Value
$3,357,096
+$537,068 QoQ
Shares Held
261,864
-16.5% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026WASATCH ADVISORS LP holds $59,676,298 across 9 Biotechnology names. NTLA ranks #7 (5.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PHAT |
Phathom Pharmaceuticals, Inc.
|
1,340,916 | $14,897,576 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
|
313,158 | $10,190,161 | |
| 3 | DYN |
Dyne Therapeutics, Inc.
|
443,668 | $8,043,700 | |
| 4 | CCCC |
C4 Therapeutics, Inc.
|
2,961,761 | $7,789,431 | |
| 5 | IMTX |
Immatics N.V.
|
464,823 | $4,573,858 | |
| 6 | MGNX |
Macrogenics Inc
|
1,559,701 | $4,507,535 | |
| 7 | NTLA |
Intellia Therapeutics, Inc.
This page
|
261,864 | $3,357,096 | |
| 8 | NKTX |
Nkarta, Inc.
|
1,577,847 | $3,329,257 |
All Filings in NTLA
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,357,096 | 261,864 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $2,820,028 | 313,685 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||